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Abstract: Purpose: Vitamin D is hypothesized to suppress inflammation, and circulating 25-
hydroxyvitamin D (25OHD) and inflammatory markers are inversely correlated.
However, total serum 25OHD may not be the best indicator of biologically active
vitamin D.
Methods: We tested serum total 25OHD, total 1,25(OH)2D, vitamin D binding protein
(DBP), and estimated free 25OHD  and free 1,25(OH)2D associations with
inflammatory markers serum IL-6, TNFα and their soluble receptors, IL-10 and CRP as
continuous outcomes and the presence of ≥2 inflammatory markers in the highest
quartile as a dichotomous outcome,  in a random subcohort of 679 men in the
Osteoporotic Fractures in Men (MrOS) study.
Results: IL-6 was lower in men with higher 25OHD (-0.23 µg/mL per SD increase in
25OHD, 95% CI: -0.07 to -0.38 µg/mL) and with higher 1,25(OH)2D (-0.20 µg/mL, 95%
CI: -0.0004 to -0.39 µg/mL); free D associations were slightly stronger. 25OHD and
DBP, but not 1,25(OH)2D, were independently associated with IL-6. TNFα soluble
receptors were inversely associated with 1,25(OH)2D  but positively associated with
25OHD, and each had independent effects. The strongest association with ≥2
inflammatory markers in the highest quartile was for free 1,25(OH)2D (OR: 0.70, 95%
CI: 0.54 to 0.89 per SD increase in free 1,25(OH)2D).
Conclusions: Associations of 1,25(OH)2D and free 25OHD with IL-6 mirrored those of
25OHD, suggesting that 1,25(OH)2D and free D do not improve upon 25OHD in
population-based IL-6 studies. However, associations for the two metabolites diverged
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for TNFα soluble receptor, warranting examination of both metabolites in studies of
TNFα and its antagonists.
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Dear Drs. Lindsay and Kanis,
Thank you for the opportunity to resubmit "Associations of total and free 25OHD and
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each reviewer's comment, as described in the attachment, and believe the revisions
have resulted in a much stronger manuscript.
Sincerely,
Carrie Nielson, PhD, MPH
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Response to Reviewers: COMMENTS FOR THE AUTHOR:
Reviewer #1:
This manuscript explores the relationships between measures of vitamin D and
inflammatory markers in a cross-sectional analysis.  The main concern is the
considerable number of associations assessed with no account taken of multiple
testing.
Could the authors please estimate the number of different associations assessed in the
various tables and then attempt to take this into account appropriately to reduce the
risk of type II error.
Response: We are examining associations between five vitamin D metabolites – total
25(OH)D, total 1,25(OH)2D, free 25(OH)D, free 1,25(OH)2D and vitamin D binding
protein (DBP) and six inflammatory markers (including soluble receptors) – IL-6, IL-
6sR, TNFα, TNFα-sRI, TNFα-sRII and CRP, and, one anti-inflammatory marker – IL-
10.  That sums up to thirty-five associations of interest.  The Bonferroni adjusted alpha
is 0.001 (0.05/35).  We have added this to the statistical methods section (lines 201-
203) and a footnote to all tables for significant associations at the Bonferroni adjusted
alpha.
On a similar point, in addition to the multiple inflammatory markers assessed, the
authors produce a composite score of inflammatory markers.  This appears fairly
arbitrary.  Please could you authors justify the use of this outcome (including the
thresholds chosen) if it is to remain in the analysis.
Response: This is an attempt to examine the overall profile of a subject that may have
elevated levels of more than one inflammatory marker.  The profile of an individual
having elevated levels of only one inflammatory marker might be different from the
profile of an individual who might have elevated levels of more than one inflammatory
marker.  We do realize that there might be more than one method of computing a
composite inflammatory score like a z-score (Hopkins, M.F., (2012), Associations of
Circulating Inflammatory Biomarkers with Risk Factors for Colorectal Cancer in
Colorectal Adenoma Patients, Biomarker Insights). The method we presented has also
been previously published in multiple studies (Inflammatory markers and incident
fracture risk in older men and women: the Health Aging and Body Composition Study.
J Bone Miner Res 22:1088-1095, Inflammatory markers and risk of hip fracture in older
white women: the study of osteoporotic fractures. J Bone Miner Res 29(9):2057-64,
Inflammatory markers and the risk of hip fracture: the Women's Health Initiative. J
Bone Miner Res 27(5):1167-76, Inflammatory markers and incident mobility limitation in
the elderly. J Am Geriatr Soc 52(7):1105-13) and represents a more specific indicator
of systemic inflammation than a high level of just one inflammatory marker.  We have
added this limitation to the Discussion (line 306-309).
Why have the authors assessed correlations and then linear regressions for
relationships between inflammatory markers and vitamin D?  Furthermore, why have
they then presented them in different parts of the results as if they are completely
separate analyses?  Perhaps the objective of the study in the introduction could be
expanded and made more specific than just "examine associations" to justify why
correlations and regressions are both necessary (if they are both needed).
Response: We provide correlations as a supplemental table in order to show
correlations among the independent variables and among the dependent variables,
whereas the association analyses show the relationship between each independent
and dependent variable.  Although correlations among vitamin D variables are
moderate to strong, and among inflammatory markers most correlations are weak to
moderate, the correlations between them are weak (Results section lines 211 to 215).
Correlations are only able to assess unadjusted strength of association, whereas linear
regression modelling provides multiply adjusted estimates of magnitude of
associations.  Hence, the decision to examine correlations and linear regression
modelling to quantify inflammatory markers and vitamin D associations.
Supplementary table 1 is very confusing.  Could the variables not be listed in a more
Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation
intuitive way?  This will depend on the research question you are trying to answer (see
above).
Response: The table has been rearranged to have all vitamin D metabolites together
and all inflammatory markers together so it has better readability.
In table 1, the superscript "a" is used to mean two different things.
Response: Thank you for pointing out the error.  It has been corrected.
Please justify presenting the raw data points in figures 2 and 3 but adding the adjusted
line of best fit.
Response: The data points in figures 2 and 3 are not raw data points.  They are
actually predicted values from our fully adjusted linear regression model with the
adjusted line of best fit added to it.  We have clarified this better by adding it to the
footnote of figures 2 and 3.
Could the authors comment on the generalisability of their results?  Is the cohort in this
specific analysis, similar to the US men in general?
Response: These results could be generalized to a predominantly non-Hispanic, white
population of older men in the US.  We have added a discussion of generalizability and
comparison to other studies that examined these associations in SLE and RA patients
to lines 293-295.
Reviewer #2: This is a interesting and well conducted study with the objective to
examine associations of total and free 25OHD and 1,25(OH)2D with serum markers of
inflammation. The topic is current and the results might have important clinical
implications (measurement of 1,25(OH)2D as independent predictor of inflammatory
state ?) and interesting speculations (dichotomous functions for the two vitamin D
metabolites in TNFα pathway).
I have only few comments:
1.    I suggest to expand the background adding some clinical example about the
correlation between vitamin D deficiency and increase inflammation:  Rossini M,
Maddali Bongi S, La Montagna G, et al. Vitamin D deficiency in rheumatoid arthritis:
prevalence, determinants and associations with disease activity and disability. Arthritis
Res Ther 2010; 12:R216. Lange, U., Jung, O., Teichmann, J. & Neeck, G. Relationship
between disease activity and serum levels of vitamin D metabolites and parathyroid
hormone in ankylosing spondylitis. Osteoporos. Int. 12, 1031-1035 (2001). Amital H,
Szekanecz Z, Szucs G, et al. Serum concentrations of 25-OH vitamin D in patients with
systemic lupus erythematosus (SLE) are inversely related to disease activity: is it time
to routinely supplement patients with SLE with vitamin D? Ann Rheum Dis 2010;
69:1155-1157.
Response: Thank you for the references.  The background has been expanded with
these clinical examples.
2.    About the major and correctly recognized limitation of this study on the
impossibility to address the causality relationship between inflammation and vitamin D,
I suggest to add in the references the first reporting of  Ried D, Toole BJ, Knox S et al.
The relation between acute changes in the systemic inflammatory response and
plasma 25-hydroxyvitamin D concentrations after elective knee arthroplasty. Am J Clin
Nutr 2011;93:1006-11
Response: Thank you. We have added this reference to line 304.
3.    In consideration of the interesting divergent associations of vitamin D metabolites
with TNFα soluble receptors, have you any comment about the results of this study
"Welsh P, Peters MJ, McInnes IB, et al. Vitamin D deficiency is common in patients
with RA and linked to disease activity, but circulating levels are unaffected by
TNFalpha blockade: results from a prospective cohort study. Ann Rheum Dis 2011;
70:1165-1167" ?.
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Response: The Welsh et al. study is an interesting study which we suggest supports, at
least in part, our proposed explanation for the divergent effects of 25OHD and
1,25(OH)2D on soluble TNFα receptors. The Welsh et al. study assumes that TNFα is
linked to vitamin D through effects on serum 25OHD levels. Instead we contend that
the relationship is the other way round – low serum 25OHD may drive higher TNFα.
However, as we outline in the Discussion of our manuscript, TNFα levels may indeed
be subject to regulation by the active form of vitamin D, 1,25(OH)2D.  This was not
measured in the study by Welsh et al. but, as shown in our study, higher 1,25(OH)2D is
associated with higher soluble receptor for TNFα. Conversion of 25OHD to
1,25(OH)2D is known to be stimulated by cytokines such as TNFα, so the induction of
soluble TNFα receptors following the synthesis of 1,25(OH)2D may be part of a
feedback control linking vitamin D and TNFα.  It will certainly be interesting to assess
the effects of TNFα blockade on serum levels of 1,25(OH)2D as well as 25OHD, and
this is something that we are planning for future studies.
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  54 
ABSTRACT (Between 150 & 250 words) (Current number of words = 248) 55 
Purpose: Vitamin D is hypothesized to suppress inflammation, and circulating 25-hydroxyvitamin D 56 
(25OHD) and inflammatory markers are inversely correlated. However, total serum 25OHD may not be the best 57 
indicator of biologically active vitamin D.  58 
Methods: We tested serum total 25OHD, total 1,25(OH)2D, vitamin D binding protein (DBP), and 59 
estimated free 25OHD  and free 1,25(OH)2D associations with inflammatory markers serum IL-6, TNFα and their 60 
soluble receptors, IL-10 and CRP as continuous outcomes and the presence of ≥2 inflammatory markers in the 61 
highest quartile as a dichotomous outcome,  in a random subcohort of 679 men in the Osteoporotic Fractures in Men 62 
(MrOS) study.  63 
Results: IL-6 was lower in men with higher 25OHD (-0.23 µg/mL per SD increase in 25OHD, 95% CI: -64 
0.07 to -0.38 µg/mL) and with higher 1,25(OH)2D (-0.20 µg/mL, 95% CI: -0.0004 to -0.39 µg/mL); free D 65 
associations were slightly stronger. 25OHD and DBP, but not 1,25(OH)2D, were independently associated with IL-6. 66 
TNFα soluble receptors were inversely associated with 1,25(OH)2D  but positively associated with 25OHD, and 67 
each had independent effects. The strongest association with ≥2 inflammatory markers in the highest quartile was 68 
for free 1,25(OH)2D (OR: 0.70, 95% CI: 0.54 to 0.89 per SD increase in free 1,25(OH)2D).  69 
Conclusions: Associations of 1,25(OH)2D and free 25OHD with IL-6 mirrored those of 25OHD, 70 
suggesting that 1,25(OH)2D and free D do not improve upon 25OHD in population-based IL-6 studies. However, 71 
associations for the two metabolites diverged for TNFα soluble receptor, warranting examination of both 72 
metabolites in studies of TNFα and its antagonists.   73 
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Mini Abstract 75 
Vitamin D is hypothesized to suppress inflammation.  We tested total and free vitamin D metabolites and their 76 
association with inflammatory markers.  Interleukin-6 levels were lower with higher 25-hydroxyvitamin D.  1,25-77 
dihydroxyvitamin D and free 25OHD associations mirrored those of 25OHD.  However, associations for the two 78 
metabolites diverged for TNFα soluble receptors. 79 
 80 
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BACKGROUND  82 
Chronic low-grade inflammation is a contributor to age-associated frailty, mortality and morbidity, including 83 
osteoporosis [1]. Inflammatory markers such as interleukin-6 (IL-6) and tumor necrosis factor alpha (TNFα) are 84 
implicated in the process of vascular calcification and regulation of bone remodeling [2, 3] and have been linked to 85 
incident fracture [4] and BMD loss [5].  86 
Vitamin D has direct effects on bone health and may also act on bone by modulating inflammation [6, 7]. We 87 
have recently shown that low 1,25(OH)2D and 25OHD are independently associated with hip fracture in older men, 88 
but only 25OHD was independently associated with BMD loss [8].   1,25(OH)2D3 may also play a role in regulating 89 
both the inflammatory process and bone turnover.  Decreased 1,25(OH)2D3 levels may contribute to inhibition of 90 
bone formation and suppress activated T cells and cell proliferation, which may accelerate the inflammation process 91 
in those with conditions such as ankylosing spondylitis (AS) [9].   92 
In vitro and in vivo evidence suggests that the biologically active form of vitamin D, 1,25(OH)2D, has several 93 
immunomodulatory functions, including suppression of pro-inflammatory marker expression and regulation of 94 
immune cell activity [10]. Treatment of fibroblast cultures with 1,25(OH)2D3 inhibits IL-6 and interleukin-8 (IL-8) 95 
[11]. Vitamin D inhibits the activation of the TNFα converting enzyme and subsequent inflammation on multiple 96 
levels [10, 12, 13].  Studies of vitamin D and inflammatory diseases, such as rheumatoid arthritis (RA) and systemic 97 
lupus erythematosus, suggest a role for vitamin D deficiency in inflammation [14-17].  However, little is known 98 
about the relationship between inflammation and vitamin D in the general population.  99 
The objective of this study was to examine associations of  total and free circulating 25OHD and 1,25(OH)2D 100 
and vitamin D binding protein (DBP) with inflammatory markers that include CRP, IL-6, TNFα, IL-6 and TNFα 101 
soluble receptors, and one anti-inflammatory cytokine – interleukin-10 (IL-10) in a cohort of older men. 102 
 103 
METHODS 104 
Study Design 105 
The Osteoporotic Fractures in Men Study (MrOS) is a prospective observational cohort study designed to 106 
determine risk factors for osteoporosis and age-related medical conditions in men 65 years of age and older. This 107 
study is conducted at six centers in the United States: Birmingham, Alabama; Minneapolis, Minnesota; Palo Alto, 108 
California; Pittsburgh, Pennsylvania; Portland, OR; and San Diego, California. Participants were recruited by 109 
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mailings to the Department of Motor Vehicles (DMV), voter registration and participant databases, community and 110 
senior newspaper features and advertisements, and targeted presentations, from March 2000 through April 2002. 111 
Exclusion criteria were (1) inability to walk without assistance from another person, (2) bilateral hip replacements, 112 
(3) inability to provide self-reported data, (4) residence not near a study site, (5) judged by an investigator to have a 113 
medical condition that would result in early death, (6) and inability to understand and sign informed consent [18, 114 
19].  115 
Vitamin D Measurements 116 
Serum concentrations of both the inactive (25OHD) and active (1,25(OH)2D) forms of vitamin D were 117 
analyzed in a random sample of men from the baseline visit of the MrOS study.  Additional assays were carried out 118 
to measure vitamin D binding protein (DBP), the major serum protein carrier of vitamin D metabolites.  Assays 119 
were completed in December 2012 using stored serum collected at the MrOS baseline visit. At the baseline visit, 120 
fasting morning blood samples were collected; serum was separated immediately after phlebotomy, and then stored 121 
at −70°C. All samples for total 25OHD remained frozen in foil wrapped vials to reduce UV exposure until assay.  122 
Measures for 25OHD2 (derived from ergocalciferol) and 25OHD3 (derived from cholecalciferol) were 123 
performed at the Mayo Clinic using mass spectrometry as previously described [20, 21]. Deuterated stable isotope 124 
(d3-25OHD) was added to a 0.2-ml serum sample as internal standard. 25OHD2, 25OHD3, and the internal standard 125 
were extracted using acetonitrile precipitation. Extracts were further purified online and analyzed by liquid 126 
chromatography/tandem mass spectrometry using multiple reaction monitoring. 25OHD2 and 25OHD3 were 127 
reported individually. The minimum detectable limit was 4 ng/ml for 25OHD2 and 2 ng/ml for 25OHD3.  Aliquots 128 
of a single serum pool were included in alternate assay runs. Using the pooled serum, the interassay coefficient of 129 
variation (CV) for 25OHD3 was 4.4%, and the intraassay CV was 4.9%.  130 
Total 1,25(OH)2D was measured at the University of Leuven in Belgium, using LC-MS/MS without 131 
derivatization [22].  The lower limit of quantitation (LLQ) was 4.3 pg/mL for 1,25(OH)2D2 and 6 pg/mL for 132 
1,25(OH)2D3.  Inter-assay CV of pooled serum at low and high serum concentrations, respectively, were 10.1% for 133 
serum with mean concentration of 7.16 pg/mL and 5.9% for serum with mean concentration of 55.8 pg/mL [23]. 134 
 DBP concentration in serum was measured by a two-site polyclonal ELISA (Genway Biotech, San Diego, 135 
CA) at the OHSU Clinical and Translational Research Institute laboratory. Intra-assay CV was 3%.  Because no 136 
gold standard for DBP exists, we also measured DBP by a monoclonal ELISA (mELISA; R&D Systems, 137 
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Minneapolis, MN) and by polyclonal radial immunodiffusion assay (Laboratory of Clinical and Experimental 138 
Endocrinology, KU Leuven, Belgium), which had intra-assay CVs of 2-4% [24]. 139 
   Free 25OHD concentrations were calculated using published mathematical models that incorporates serum 140 
concentrations of 25OHD, 1,25(OH)2D, DBP, and albumin. Primary analyses were performed with estimated free 141 
25OHD that assumed constant binding affinity across GC genotypes; however, GC-genotype-specific affinity 142 
estimates were also calculated for comparison [25]. 143 
Inflammatory Markers 144 
Cytokine assays were measured in MrOS baseline samples utilizing a random sampling scheme. The assays 145 
were completed between December, 2009, and August, 2010, using archived serum collected at baseline on 1530 146 
MrOS men as part of a MrOS ancillary study. Cytokine measures used in this analysis include CRP, IL-6, TNFα, 147 
tumor necrosis factor alpha soluble receptors (TNFα-sRI, TNFα-sRII) and interleukin-6 soluble receptor (IL6-sR).  148 
IL-10 was also measured as an anti-inflammatory measure.  149 
All cytokine assays were performed at the Laboratory for Cytokine Biochemistry, University of Vermont. 150 
The samples were thawed at 37°C and briefly centrifuged. 300 μl of serum was placed into one cryovial for testing 151 
of TNFα, TNF-αsRI and sRII, IL-10 and CRP. Approximately 230 μl were plated into two plates for IL-6 and IL-152 
6sR. The plates were refrozen at -80°C until assaying. IL-6 was measured using a high sensitivity ELISA (R&D 153 
Systems, Minneapolis, MN). The assay range is 0.16 – 12.0 pg/mL. Inter-assay CVs range from 6.11 to 8.47%. IL-154 
6sR was measured using ELISA (R&D Systems, Minneapolis, MN). [26] The assay range is 3120 – 200,000 pg/mL. 155 
Inter-assay CVs range from 4.68 to 8.83%. TNFα was measured using the Human Serum CVD3 Multiplex Kit 156 
(Millipore Corp., Billerica, MA) which is run by flow cytometry on the Bio-Rad BioPlex 200 Luminex instrument. 157 
The assay range is 0.13-2000 pg/mL. Inter-assay CVs range from 4.93 to 9.13%. TNF-αsRI and sRII were measured 158 
with an ELISA (R&D Systems, Minneapolis, MN). The normal range for TNF- αsRI in serum is 479 – 966 pg/mL 159 
and for TNF-αsRII in serum is 1003 – 3170 pg/mL. Inter-assay CVs range from 5.42% to 8.59% for TNF-αsRI and 160 
2.87 to 3.54% for TNF-αsRII. CRP was measured using the BNII nephelometer from Dade Behring utilizing a 161 
particle enhanced immunonepholometric assay. The assay range is 0.16 – 1100 ug/mL. Expected values for CRP in 162 
normal, healthy individuals are ≤ 3 ug/mL. Inter-assay CVs ranged from 1.52 to 3.68%.   163 
Covariates 164 
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Demographic characteristics such as age, race/ethnicity, clinical site, and lifestyle factors including weekly 165 
alcohol consumption and smoking history were determined at baseline by questionnaire.  Physical activity was 166 
assessed with the Physical Activity Score for the Elderly (PASE) [27]. Height (centimeters) was measured on 167 
Harpenden stadiometers, and weight (kilograms) was measured on standard balance beam or digital scales. Body 168 
mass index (BMI) was calculated as kilograms per meter squared (kg/m2). Prevalent cardiovascular disease was 169 
defined as self-report of heart attack, congestive heart failure (CHF) or angina. Diabetes, stroke history, self-reported 170 
health, surgical removal of stomach/intestine and rheumatoid arthritis at baseline were also from self-report. 171 
Participants brought in all medications they used within the last 30 days. All prescription medications recorded by 172 
the clinics were stored in an electronic medications inventory database (San Francisco Coordinating Center, San 173 
Francisco, CA).  Each medication was matched to its ingredient(s) based on the Iowa Drug Information Service 174 
(IDIS) Drug Vocabulary (College of Pharmacy, University of Iowa, Iowa City, IA) [28].   175 
Serum creatinine was measured using a variation of the Jaffe enzymatic method. Renal function was 176 
expressed as estimated glomerular filtration rate (eGFR) in ml/min/1.73 m2 using a standardized serum-creatinine 177 
based formula [29]. Total fat mass was measured from dual-energy X-ray absorptiometry (DXA) scans using 178 
Hologic QDR 4500 scanners (Hologic, Inc., Bedford, MA).     179 
Statistical Analysis 180 
All vitamin D measurements were standardized by subtracting the mean from each value and dividing by 181 
the standard deviation to facilitate comparison across measures. Correlations among inflammatory markers and 182 
between the inflammatory markers and the vitamin D measures were assessed using Spearman’s correlation 183 
coefficients. We used linear regression modeling with robust standard errors to examine the effect of standardized 184 
vitamin D measurements on each inflammatory marker.  Although the inflammatory markers are right-skewed, 185 
least-squares regression methods perform well with 500 or more observations and provide 95% confidence interval 186 
coverage for all regression coefficients [30].  Betas (β) and 95% confidence intervals (CI) from the model are 187 
reported as mean difference in the inflammatory markers per standard deviation (SD) change in vitamin D 188 
measurements. To identify any nonlinear associations between each vitamin D measure and inflammatory marker, 189 
we examined loess plots.  We created an inflammatory index by summing the number of pro-inflammatory markers 190 
in the highest quartile (CRP, IL-6, TNFα, TNFα-sRI, TNFα-sRII and IL-6sR). We then dichotomized this index into 191 
those having ≥2 inflammatory markers in the highest quartile in comparison with those having <2 inflammatory 192 
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markers in the highest quartile [4]. Logistic regression modeling was used to obtain odds ratios (OR) and 193 
corresponding 95% CI.  194 
No nonlinear associations were detected between any vitamin D measurement and inflammatory marker.  195 
The base model included age, race, clinical site, and season.  We used stepwise modeling with a probability of 196 
removal at > 0.10, forcing the base model covariates of age, site, race, season and the vitamin D measure into the 197 
model and to include all covariates that were significantly associated with each inflammatory marker. All covariates 198 
that were significantly associated with any inflammatory marker were included in the final model for all 199 
inflammatory markers.  An age-squared term was added to each model to check for non-linear association with age.  200 
There are thirty-five associations of interest (five vitamin D metabolites by six inflammatory markers and one anti-201 
inflammatory marker). Thus, we have added a footnote to our tables with a Bonferroni adjusted p-value of ≤0.001 202 
(0.05/35 = 0.001). 203 
All analyses were conducted using SAS 9.3 (Cary, NC) and STATA release 12 (StataCorp, College Station, 204 
TX).  205 
RESULTS 206 
Description and correlations 207 
Men with inflammatory markers and vitamin D measures (Figure 1) had a mean age of 74 ±6 years and 208 
mean BMI of 27 ±4 kg/m2. Most (91%) were non-Hispanic white, and 85% reported excellent or good health status. 209 
16% were taking NSAIDs, and 27% reported a history of heart attack, CHF, or angina (Table 1).  210 
All correlations between inflammatory markers and vitamin D measures were weak. IL-6 was negatively 211 
correlated with total and free 25OHD and 1,25(OH)2D measures (r = -0.21 to -0.25, p<0.001). TNFα and its soluble 212 
receptors were significantly negatively correlated with total and free 1,25(OH)2D  measures (r = -0.14 to -0.35, 213 
p<0.001) but not with 25OHD.  The strongest correlation between CRP and vitamin D measures was with DBP (r = 214 
0.23, p<0.001) (Supplemental Table 1). 215 
Inflammatory marker associations with 25OHD and 1,25(OH)2D 216 
There was a significant association between lower IL-6 and higher 25OHD (0.23 pg/mL lower IL-6 per SD 217 
increase in 25OHD, 95% CI: 0.07 to 0.38 pg/mL), and this was independent of 1,25(OH)2D and DBP (Table 2).  218 
Mean TNFα was 0.21 pg/mL lower per SD increase in 25OHD but this association was not statistically significant 219 
(95% CI: -0.64 pg/mL to 0.21 pg/mL).  Results did not change after adjusting for 1,25(OH)2D and DBP (Table 2).    220 
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Associations of IL-6 with 25OHD and 1,25(OH)2D were similar (Figure 2), but statistically significant only 221 
for 25OHD.  Mean IL-6 levels were significantly lower per SD increase in 25OHD (-0.23 pg/mL per SD, 95% CI: -222 
0.38 to -0.07) and remained significant after adjusting for 1,25(OH)2D and DBP.  Mean IL-6 levels were lower by 223 
0.20 pg/mL (95% CI: 0.0004 to 0.39 pg/mL lower)  per SD increase in 1,25(OH)2D.  This association was 224 
attenuated to after 25OHD and DBP adjustment and was no longer significant.   225 
TNFα soluble receptors I and II were positively associated with 25OHD and inversely associated with 226 
1,25(OH)2D (Figure 3).  Average TNFα soluble receptors I and II were significantly lower by- 62.05 pg/mL ( 95% 227 
CI: 26.09 to 98.01 pg/mL) for TNFα-sRI and -88.83 pg/mL (95% CI: 30.64 to 147.02 pg/mL for TNFα-sRII) per SD 228 
increase in 1,25(OH)2D.  This association was strengthened with adjustment of 25OHD and DBP (Table 2).  TNFα 229 
soluble receptors I and II were higher by 34.66 pg/mL (95% CI: -4.17 to 73.48 pg/mL) and 38.32 pg/mL (95% CI: -230 
31.14, 107.78 pg/mL) per SD increase in 25OHD.  This association was also strengthened with 1,25(OH)2D and 231 
DBP adjustment (Table 2).   232 
Odds of having ≥2 inflammatory markers in the highest quartile decreased by 25% (95% CI: 3% to 42% 233 
decrease) per SD increase in total 1,25(OH)2D and was slightly strengthened with 25OHD and DBP adjustment 234 
(Table 2).  However, 25OHD itself was not associated with odds of having ≥2 inflammatory markers in the highest 235 
quartile. 236 
Inflammatory marker associations with free 25OHD, free 1,25(OH)2D and DBP 237 
Average CRP was significantly higher for each SD increase in DBP (1.11 ug/mL higher, 95% CI: 0.45 to 238 
1.76 ug/mL higher) (Table 3).  This association did not change after adjusting for 25OHD and 1,25(OH)2D (Table 239 
2).  Although there was a significant negative correlation between CRP and free 25OHD (r=-0.12, p<0.05), there 240 
was no significant association in regression analysis (β = 0.16 ug/mL; p=0.31) (Supplemental Table 1 and Table 3).  241 
Mean IL-6 levels were lower by 0.35 pg/mL (95% CI: 0.15 to 0.55 pg/mL lower) for each SD increase in free 242 
25OHD and by 0.22 pg/mL (95% CI: 0.04 to 0.39 pg/mL lower) per each SD increase in free 1,25(OH)2D.  TNFα 243 
soluble receptor I levels were lower by 61.51 pg/mL (95% CI: 26.28 to 96.73 pg/mL lower) and TNFα soluble 244 
receptor II levels were lower by 78.72 pg/mL (95% CI: 15.72 to 141.71 pg/mL) per SD increase in free 1,25(OH)2D.  245 
Odds of having ≥2 inflammatory markers in the highest quartile decreased by 30% (95% CI: 11% to 46% 246 
decrease) for each SD increase in free 1,25(OH)2D.  There was no significant association with free 25OHD (Table 247 
3). 248 
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CRP and TNFα soluble receptors’ associations with free measures of 25OHD and 1,25(OH)2D and DBP 249 
from other assays (monoclonal ELISA (R&D Systems, Minneapolis, MN) and radioimmunodiffusion assay (RID)) 250 
were similar to the polyclonal ELISA (Genway Biotech, San Diego, CA) assay, but slightly weaker.  The CRP-DBP 251 
associations were also somewhat weaker but still statistically significant.  IL-6 associations were significant for the 252 
free D measures from the RID assay, though slightly weaker, but not significant for the free D measures from the 253 
monoclonal ELISA assay (Supplemental Table 2).  Use of GC-genotype-specific binding affinities, rather than 254 
constant affinities, in the free D estimating equations did not make a substantial difference in associations.    255 
DISCUSSION 256 
In this study of older men, 25OHD and 1,25(OH)2D were negatively associated with IL-6 with similar 257 
magnitudes. On the other hand, associations with TNFα soluble receptors were positive for 25OHD and negative for 258 
1,25(OH)2D. DBP was positively associated with CRP, and had a weak positive association with IL-6. Perhaps for 259 
this reason, free vitamin D measures, which incorporate DBP, had slightly stronger associations with IL-6 than total 260 
vitamin D measures.  We did not observe any significant associations with TNFα, IL-10, or IL-6sR. These results 261 
indicate that 1,25(OH)2D and free D do not improve upon 25OHD in population-based IL-6 studies. However, 262 
examination of both 25OHD and 1,25(OH)2D are warranted in studies of TNFα soluble receptors.   263 
Our results support the role of serum IL-6 as a marker of the proposed anti-inflammatory effects of vitamin 264 
D.  The observed associations of 25OHD and IL-6 were consistent with previous reports in older Irish adults [31], 265 
although we observed somewhat higher median IL-6 levels across the 25OHD range.  The inverse correlation 266 
between IL-6 and both total and free forms of both vitamin D metabolites supports previous reports that this 267 
cytokine is a target for vitamin D within the immune system.  This is supported by mechanistic studies [32], for 268 
example, demonstrating that 1,25(OH)2D treatment in cell cultures inhibited p38 and lowered downstream 269 
production of IL-6 [33].   270 
CRP is also an established systemic marker of inflammation, but it was not associated with either 25OHD 271 
or 1,25(OH)2D in our study but instead was associated with levels of their serum carrier, DBP.  CRP was shown to 272 
be associated with 25OHD among older Irish adults [31] and with 1,25(OH)2D3 in ankylosing spondylitis patients 273 
[9]. But CRP levels were much higher in those studies, while in MrOS, CRP remained low across the range of 274 
25OHD and 1,25(OH)2D (<1.5 µg/ml). Similar to our results, adults in the Framingham Offspring Study had no 275 
difference in CRP by 25OHD concentration [34].  We can speculate that the association between CRP and DBP may 276 
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reflect the potential impact of systemic inflammatory cytokines on liver production of DBP [35], although a link 277 
between inflammation, CRP and DBP has not been demonstrated in other studies [36].   278 
Soluble TNFα receptors are another important marker of inflammation in that they represent potential 279 
antagonists of TNFα function. In this study, 25OHD was positively associated and 1,25(OH)2D was negatively 280 
associated with TNFα SRI and II, suggesting dichotomous functions for the two vitamin D metabolites.  We 281 
speculate that soluble TNFα receptors may be an important novel target for 25OHD as an anti-inflammatory agent. 282 
Specifically, the upregulated TNFα sRI and II may provide a sensitive mechanism by which localized conversion of 283 
25OHD to 1,25(OH)2D can abrogate inflammatory TNFα responses.      284 
An alternative hypothesis for the negative correlations between inflammatory markers and vitamin D 285 
metabolites could be that circulating cytokines regulate serum vitamin D metabolites.  The renal vitamin D-286 
activating enzyme 1α-hydroxylase (CYP27B1) is mainly regulated by serum PTH and FGF23 but extra renal 287 
production of 1,25(OH)2D by CYP247B1 is known to be induced by inflammatory cytokines such as TNFα [37-40].  288 
Further characterization of this novel component of vitamin D and inflammation will be important in future studies 289 
of vitamin D and inflammation in the elderly, especially in those with increased inflammatory disease activity such 290 
as RA patients [41]. 291 
This is the first study to compare multiple measures of vitamin D and their associations with inflammatory 292 
markers in older adults. While other studies have examined Vitamin D metabolite levels in those with SLE and RA 293 
[14, 15], the MrOS study represents a predominantly healthy older male population, non-Hispanic white population 294 
with a very low prevalence of RA (5%).  If 1,25(OH)2D is confirmed to be an independent predictor of 295 
inflammatory state, it may be a useful marker in supplementation studies and for clinical detection of vitamin D 296 
deficiency.  In the current study, 1,25(OH)2D was more strongly associated than 25OHD with TNFα soluble 297 
receptors and with having ≥2 inflammatory markers in the top quartile. 298 
We note limitations in our study. A substantial barrier to interpretation of vitamin D and inflammation 299 
studies is the question of whether inflammation also affects vitamin D.  Due to the cross-sectional, observational 300 
nature of this analysis, we are unable to address the directionality. It is possible that inflammation affects vitamin D, 301 
rather than the reverse. For example, a recent study of  patients undergoing elective hip or knee surgery recruited 302 
from orthopedic outpatient clinics showed orthopedic surgery patients had decreases in 25OHD3, 25(OH)D and 303 
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1,25(OH)2D as a systemic inflammatory response [42, 43]. However, RCTs [6, 44-47] and in vitro evidence also 304 
support a role for 1,25(OH)2D3 on inflammation [12, 13, 25, 48] through inhibition of IL-6 and IL-8 synthesis [11].    305 
The choice of a composite inflammatory score is somewhat arbitrary, and there are multiple methods of 306 
computing a composite inflammatory score [49].  The method we presented in this paper of examining those with 307 
two or more inflammatory markers in the top quartile has also been published previously and represents a more 308 
specific indicator of systemic inflammation than a high level of just one inflammatory marker [4, 50-52]. 309 
As in any observational study, the possibility for residual confounding remains. The MrOS cohort is well 310 
characterized in terms of body composition and used an extensive medical history questionnaire and medication 311 
inventory to capture potentially confounding variables. In this analysis, we adjusted for multiple variables known or 312 
suspected to be associated with inflammatory disease and vitamin D status. However, misclassification and 313 
unmeasured confounders could still have blunted or magnified associations between vitamin D and inflammation.  314 
Estimations and direct measurements of circulating free 25OHD are not as yet standardized, and there is no 315 
gold standard for either DBP or free 25OHD assays. This limits our ability to conclude whether free 25OHD or free 316 
1,25(OH)2D can improve the  prediction of inflammatory markers or their downstream effects on health outcomes. 317 
However, our inclusion of multiple DBP measures and their estimates of free vitamin D provides the most thorough 318 
analyses of this question to date and suggests that further studies of free 25OHD and its role in inflammation are 319 
warranted. 320 
In conclusion, IL-6 associations with 25OHD have been consistent in several population-based and clinical 321 
studies, and we observed no added information in considering free 25OHD or 1,25(OH)2D. In contrast, we observed 322 
consistently divergent associations with TNFα soluble receptors for these metabolites. Considering the importance 323 
of TNFα action in osteoclastic maturation [7, 53, 54], future studies of vitamin D should include investigations of 324 
the effects of each metabolite.  325 
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Table 1. Baseline characteristics, MrOS  326 
Characteristic Overall (N=679) 
Mean ±SD, Median (IQR) or n(%) 
Age 74 ± 6 
Race  
   White 616 (90.72) 
   African American 22 (3.24) 
   Asian 16 (2.36) 
   Hispanic 17 (2.50) 
   Other 8 (1.18) 
Vitamin D  
   25OHD (ng/ml) 25.95 ±7.98 
   Free 25OHD (nmol/L) 0.03 ±0.01 
   1,25(OH)2D (pg/ml) 64.24 ±71.72 
   Free 1,25(OH)2D (nmol/L) 0.0015 ±0.0004 
  Vitamin D binding protein (µM) 4.36 ±0.75 
Season of blood draw  
   Winter 134 (19.73) 
   Spring 174 (45.36) 
   Summer 198 (29.16) 
   Fall 173 (25.48) 
BMI (kg/m2) 27 ±4 
Total Fat Mass (kg) § 22 ±7 
Inflammatory Markers  
   CRP (ug/mL)§ a 1.44 (2.1) 
   IL-6 (pg/mL)§ a 2.37 (1.97) 
   TNFα (pg/mL)§ a 3.96 (2.54) 
Soluble Receptors  
   TNFα-sRI (pg/mL)§ a 1940.60 (593.40) 
   TNFα-sRII (pg/mL)§ a 3521.80 (938.90) 
   IL-6sR (ng/ml)§ a 49.09 (18.25) 
Anti-Inflammatory Marker  
IL-10 (pg/mL) § a 8.85 (6.93) 
Alcohol (per week)  
   0 drinks 238 (35.05) 
   1-7 drinks 323 (47.57) 
   >7 drinks 118 (17.38) 
Self-reported quality of health*  
   Excellent/Good 576 (84.96) 
   Fair/Poor/Very Poor 102 (15.04) 
PASE score† 147 ±66 
NSAIDS use§ 107 (16.49) 
Corticosteroid use§ 53 (8.17) 
Cox-II inhibitor use 51 (7.86) 
CVDb 182 (26.80) 
Stroke 51 (7.51) 
Diabetes 83 (12.22) 
Surgical removal of stomach or intestine 56 (8.25) 
Rheumatoid Arthritis 34 (5.01) 
Renal Function  
   eGFR (ml/min/(1.73m2) § 77 ±19 
   Serum creatinine (mg/dl) § 1.02 ±0.30 
* How would you rate your overall health? 327 
†  Physical activity score for the elderly 328 
a  median, inter-quartile range (IQR)  329 
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§  5 missing total fat mass, 36 missing lipids, 80 missing CRP, 83 missing IL-6, 81 missing TNFα, 66 missing, 330 
TNFα-sRI, 72 missing TNFα-sRII, 66 missing IL-6sR, 71 missing IL-10, 36 missing eGFR, 36 missing serum 331 
creatinine, 30 missing NSAIDS use, 30 missing corticosteroid use, 30 missing Cox-II inhibitor 332 
b  defined as self-report of previous  heart attack, congestive heart failure or angina 333 
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Table 2. Associations with each inflammatory marker (βc, 95% CI) per SD increase in total vitamin D measure, MrOS  334 
 N 25OHD 1,25(OH)2D 25OHD 1,25(OH)2D DBP 
  (SD=7.98 ng/ml) (SD=71.72 pg/ml) 25OHD, 1,25(OH)2D, and DBP in the same model 
IL-6 (pg/mL)  557 -0.23 (-0.38, -0.07)** -0.20 (-0.39, -0.0004)* -0.21 (-0.37, -0.04)* -0.14 (-0.35, 0.06) 0.15 (0.007, 0.30)* 
IL-6sR (ng/mL) 571 0.39 (-.88, 1.67) 0.20 (-1.00, 1.42) 0.26 (-1.11, 1.64) 0.04 (-1.23, 1.31) 0.54 (-0.50, 1.58) 
TNFα (pg/mL) 556 -0.23 (-0.65, 0.18) -0.19 (-0.43, 0.06) -0.21 (-0.64, 0.21) -0.12 (-0.34, 0.10) 0.11 (-0.09, 0.30) 
TNFα-sRI (pg/mL) 571 34.66 (-4.17, 73.48) -62.05 (-98.01, -26.09)*** 62.30 (21.33, 103.28)** -86.53 (-124.18, -48.87)** 16.20 (-15.36, 
47.76) 
TNFα-sRII (pg/mL) 565 38.32 (-31.14, 107.78) -88.83 (-147.02, -30.64)** 79.20 (5.53, 152.88)* -118.75 (-180.45, -57.06)** 9.75 (-45.92, 65.42) 
IL-10 (pg/mL) 566 -1.18 (-4.33, 1.97) -1.77 (-3.74, 0.19) -0.77 (-3.96, 2.41) -1.62 (-3.49, 0.25) 0.83 (-0.38, 2.04) 
CRP (µg/mL) 557 0.48 (-0.44, 1.40) 0.07 (-0.35, 0.48) 0.33 (-0.58, 1.24) -0.20 (-0.66, 0.27) 1.08 (0.50, 1.65)** 
≥2 inflammatory 
markers in highest 
quartile§ (N=571) 
571 0.98 (0.77, 1.26) 0.75 (0.58, 0.97)* 1.03 (0.79, 1.35) 0.72 (0.55, 0.95)* 1.29 (1.04, 1.59)* 
cAdjusted for age, site, race, total fat mass, serum creatinine, eGFR, smoking, alcohol, season, self-reported health, diabetes, stroke, cox-II inhibitor use, surgical 335 
removal of stomach or intestine. 336 
§Among CRP, IL-6, TNFα, TNFα-sRI, TNFα-sRII, IL-6sR. Effect measure = odds ratios (95%CI).  **p≤0.01, *p≤0.05, ***p≤0.001 (Bonferroni-corrected alpha) 337 
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Table 3. Associations with each inflammatory marker (βc, 95% CI) per SD increase in free vitamin D and binding protein (DBP) measures, MrOS 340 
 N Free 25OHD 
(SD=0.01 nmol/L) 
Free 1,25(OH)2D 
(SD=0.0004 nmol/L) 
DBP 
(SD=0.75 µM) 
IL-6 (pg/mL) 557 -0.35 (-0.55, -0.15)** -0.22 (-0.39, -0.04)* 0.11 (-0.04, 0.26) 
IL-6sR (ng/mL) 571 0.20 (-1.55, 1.96) -0.02 (-1.23, 1.18) 0.59 (-0.41, 1.59) 
TNFα (pg/mL) 556 -0.36 (-0.93, 0.20) -0.21 (-0.45, 0.03) 0.06 (-0.14, 0.25) 
TNFα-sRI (pg/mL) 571 39.67 (-13.42, 92.76) -61.51 (-96.73, -26.28)** 16.70 (-14.91, 48.32) 
TNFα-sRII (pg/mL) 565 51.01 (-44.53, 146.55) -78.72 (-141.71, -15.72)* 9.86 (-44.12, 63.83) 
IL-10 (pg/mL) 566 -2.15 (-6.18, 1.88) -1.93 (-3.81, -0.05)* 0.54 (-0.76, 1.84) 
CRP (µg/mL) 557 0.16 (-0.98, 0.67) -0.40 (-0.79, -0.02)* 1.11 (0.45, 1.76)*** 
≥2 inflammatory markers 
in highest quartile§ 
(N=571) 
571 0.85 (0.61, 1.19)  0.70 (0.54, 0.89)** 1.26 (1.03, 1.55)* 
cAdjusted for age, site, race, total fat mass, serum creatinine, eGFR, smoking, alcohol, season, self-reported health, diabetes, stroke, cox-II inhibitor use, surgical 341 
removal of stomach or intestine. 342 
§Among CRP, IL-6, TNFα, TNFα-sRI, TNFα-sRII, IL-6sR. Effect measure = odds ratios (95%CI).  **p≤0.01, *p≤0.05, ***p≤0.001 (Bonferroni-corrected alpha) 343 
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Figure 1. MrOS analytic sample size, randomly selected from the full MrOS cohort (N=5994) 345 
 346 
 347 
 348 
  349 
  
Random sample of  
980 participants  with 
5 or more stored 
serum vials for 
cytokine data. 
679 participants in 
the vitamin D and 
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Figure 2. The IL-6 association with standardized 25OHD was nearly identical to the association with 1,25(OH)2D.  Data points are predicted valuesb.  350 
 351 
 352 
b Data points and lines are from a fully adjusted regression model (adjusted for age, site, race, total fat mass, serum creatinine, eGFR, smoking, alcohol, season, 353 
self-reported health, diabetes, stroke, cox-II inhibitor use, surgical removal of stomach or intestine) with both vitamin D measures and DBP in the same model. 354 
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Figure 3. The TNFα soluble receptors I (top panels) and II (lower panels) associations with standardized 25OHD and 1,25(OH)2D, were in opposite directions.  357 
Data points are predicted valuesb. 358 
 359 
 360 
b Data points and lines are from a fully adjusted regression model (adjusted for age, site, race, total fat mass, serum creatinine, eGFR, smoking, alcohol, season, 361 
self-reported health, diabetes, stroke, cox-II inhibitor use, surgical removal of stomach or intestine) with both vitamin D measures and DBP in the same model.362 
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Supplemental Tables 363 
 364 
Supplemental Table 1: Spearman correlations among Vitamin D measures and inflammatory markers 365 
 Total 25OHD Free 
25OHD 
Total 
1,25(OH)
2D 
Free 
1,25(OH)
2D 
VDBP 
(polyclon
al 
ELISA) 
VDBP 
(mono-
clonal 
ELISA) 
VDBP 
(RIA) 
IL-6 TNFα TNFα-
sRI 
TNFα-sRII IL-6sR 
Total 25OHD     0.17*** 0.19*** 0.23***      
Free 25OHD 0.87***    -0.27*** -0.59*** -0.21***      
Total 1,25(OH)2D 0.35*** 0.32***   0.09 0.09* 0.17***      
Free 1,25(OH)2D 0.28*** 0.43*** 0.91***  -0.29*** -0.62*** -0.20***      
IL-6 -0.21*** -0.21*** -0.25*** -0.24*** 0.03 -0.01 -0.06      
TNFα -0.03 -0.04 -0.14*** -0.15*** 0.01 0.08 0.04 0.24***     
TNFα-sRI -0.01 -0.01 -0.35*** -0.34*** 0.03 0.04 -0.07 0.43*** 0.38***    
TNFα-sRII -0.02 -0.02 -0.31*** -0.29*** -0.004 0.03 -0.09* 0.40*** 0.42*** 0.84***   
IL-6sR 0.01 -0.01 -0.05 -0.06 0.05 0.03 0.12*** 0.13*** 0.11*** 0.15*** 0.15***  
CRP -0.04 -0.12* -0.08 -0.16*** 0.23*** 0.10* 0.16*** 0.45*** 0.18*** 0.29*** 0.26*** 0.05 
IL-10 0.09 0.06 0.002 -0.007 0.02 0.13*** 0.05 0.09* 0.38*** 0.22*** 0.24*** 0.03 
* p<0.05, ** p<0.01, ***p<0.001.  366 
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Supplement Table 2. Associations with inflammatory markers (β, 95% CI) for each SD increase in free vitamin D and binding protein (DBP measures, MrOS) 369 
 Free 25OHD Free 1,25(OH)2D DBP 
 (Using DBP from 
monoclonal ELISA) 
(Using DBP from 
RIA) 
(Using DBP from 
monoclonal ELISA) 
(Using DBP from 
RIA) 
(Using DBP from 
monoclonal ELISA) 
(Using DBP from 
RIA) 
IL-6 (pg/mL) 
(N=557) 
-0.03 (-0.20, 0.15) -0.31 (-0.51, -
0.10)** 
-.0.09 (-0.27, 0.09) -0.18 (-0.36, 0.01) 0.05 (-0.10, 0.20) 0.01 (-0.13, 0.16) 
IL-6sR (ng/mL) 
(N=571) 
0.90 (-0.19, 1.99) -0.21 (-1.95, 1.52) 0.73 (-0.33, 1.78) -0.31 (-1.50, 0.88) 0.59 (-0.51, 1.69) 1.31 (0.31, 2.32)* 
TNFα (pg/mL) 
(N=556) 
0.01 (-0.34, 0.36) -0.42 (-0.97, 0.12) 0.0003 (-0.25, 0.25) -0.25 (-0.47, -
0.03)* 
0.005 (-0.43, 0.44) 0.15 (-0.03, 0.34) 
TNFα-sRI 
(pg/mL) (N=571) 
53.24 (17.40, 89.08) 41.79 (-11.01, 
94.60) 
-5.98 (-42.05, 30.71) -64.66 (-97.47, -
31.85)** 
35.58 (0.58, 70.58)* 16.95 (-18.36, 52.26) 
TNFα-sRII 
(pg/mL) (N=565) 
2.05 (-59.55, 63.66) 57.97 (-37.49, 
153.42) 
-52.32 (-106.80, 2.16) -79.96 (-139.29, -
20.62)** 
46.27 (-11.82, 
104.35) 
0.76 (-53.54, 55.06) 
IL-10 (pg/mL) 
(N=566) 
2.71 (-1.50, 6.92) -2.22 (-6.44, 2.00) 1.56 (-0.86, 3.98) -2.11 (-3.86, -
0.37)* 
-0.66 (-4.42, 3.11) 0.92 (-0.46, 2.31) 
CRP (ug/mL) 
(N=557) 
0.27 (-0.39, 0.93) 0.24 (-1.01, 1.49) 0.09 (-0.43, 0.61) -0.19 (-0.61, 0.23) 0.44 (-0.10, 0.98) 0.70 (0.35, 1.04)*** 
≥2 inflammatory 
markers in 
highest quartile§ 
(N=571) 1.09 (0.86, 1.39) 0.89 (0.63, 1.25) 0.85 (0.68, 1.07) 0.71 (0.55, 0.91)** 1.21 (0.97, 1.51) 1.20 (0.97, 1.49) 
Adjusted for age, site, race, total fat mass, serum creatinine, eGFR, smoking, alcohol, season, self-reported health, diabetes, stroke, cox-II inhibitor use, surgical 370 
removal of stomach or intestine. 371 
§Among CRP, IL-6, TNFα, TNFα-sRI, TNFα-sRII, IL-6sR. Effect measure = odds ratios. 372 
**p≤0.01, *p<0.05, ***p≤0.001 (Bonferroni-corrected alpha) 373 
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  54 
ABSTRACT (Between 150 & 250 words) (Current number of words = 248) 55 
Purpose: Vitamin D is hypothesized to suppress inflammation, and circulating 25-hydroxyvitamin D 56 
(25OHD) and inflammatory markers are inversely correlated. However, total serum 25OHD may not be the best 57 
indicator of biologically active vitamin D.  58 
Methods: We tested serum total 25OHD, total 1,25(OH)2D, vitamin D binding protein (DBP), and 59 
estimated free 25OHD  and free 1,25(OH)2D associations with inflammatory markers serum IL-6, TNFα and their 60 
soluble receptors, IL-10 and CRP as continuous outcomes and the presence of ≥2 inflammatory markers in the 61 
highest quartile as a dichotomous outcome,  in a random subcohort of 679 men in the Osteoporotic Fractures in Men 62 
(MrOS) study.  63 
Results: IL-6 was lower in men with higher 25OHD (-0.23 µg/mL per SD increase in 25OHD, 95% CI: -64 
0.07 to -0.38 µg/mL) and with higher 1,25(OH)2D (-0.20 µg/mL, 95% CI: -0.0004 to -0.39 µg/mL); free D 65 
associations were slightly stronger. 25OHD and DBP, but not 1,25(OH)2D, were independently associated with IL-6. 66 
TNFα soluble receptors were inversely associated with 1,25(OH)2D  but positively associated with 25OHD, and 67 
each had independent effects. The strongest association with ≥2 inflammatory markers in the highest quartile was 68 
for free 1,25(OH)2D (OR: 0.70, 95% CI: 0.54 to 0.89 per SD increase in free 1,25(OH)2D).  69 
Conclusions: Associations of 1,25(OH)2D and free 25OHD with IL-6 mirrored those of 25OHD, 70 
suggesting that 1,25(OH)2D and free D do not improve upon 25OHD in population-based IL-6 studies. However, 71 
associations for the two metabolites diverged for TNFα soluble receptor , warranting examination of both 72 
metabolites in studies of TNFα and its antagonists.   73 
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Mini Abstract 75 
Vitamin D is hypothesized to suppress inflammation.  We tested total and free vitamin D metabolites and their 76 
association with inflammatory markers.  Interleukin-6 levels were lower with higher 25-hydroxyvitamin D.  1,25-77 
dihydroxyvitamin D and free 25OHD associations mirrored those of 25OHD.  However, associations for the two 78 
metabolites diverged for TNFα soluble receptors. 79 
 80 
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BACKGROUND  82 
Chronic low-grade inflammation is a contributor to age-associated frailty, mortality and morbidity, including 83 
osteoporosis [1]. Inflammatory markers such as interleukin-6 (IL-6) and tumor necrosis factor alpha (TNFα) are 84 
implicated in the process of vascular calcification and regulation of bone remodeling [2, 3] and have been linked to 85 
incident fracture [4] and BMD loss [5].  86 
Vitamin D has direct effects on bone health and may also act on bone by modulating inflammation [6, 7]. We 87 
have recently shown that low 1,25(OH)2D and 25OHD are independently associated with hip fracture in older men, 88 
but only 25OHD was independently associated with BMD loss [8].   1,25(OH)2D3 may is also play a  possible 89 
candidate for mediatory function role in regulating both the inflammatory process and bone turnover.  Decreased 90 
1,25(OH)2D3 levels may contribute to inhibition of bone formation and suppress activated T cells and cell 91 
proliferation, which may accelerate the inflammation process in those with conditions such as ankylosing spondylitis 92 
(AS) [9].   93 
In vitro and in vivo evidence suggests that the biologically active form of vitamin D, 1,25(OH)2D, has several 94 
immunomodulatory functions, including suppression of pro-inflammatory marker expression and regulation of 95 
immune cell activity [10].(ref Zhang). Treatment of fibroblast cultures with 1,25(OH)2D3 inhibits IL-6 and 96 
interleukin-8 (IL-8) [11]. Vitamin D inhibits the activation of the TNFα converting enzyme and subsequent 97 
inflammation on multiple levels [10, 12, 13].  Studies of vitamin D and inflammatory diseases, such as rheumatoid 98 
arthritis (RA) and systemic lupus erythematosus, suggest a role for vitamin D deficiency in 99 
However, little is known about the relationship between inflammation and vitamin D in the general population. 100 
The objective of this study was to examine associations of  total and free circulating 25OHD and 1,25(OH)2D 101 
and vitamin D binding protein (DBP) with inflammatory markers that include CRP, IL-6, TNFα, IL-6 and TNFα 102 
soluble receptors, and one anti-inflammatory cytokine – interleukin-10 (IL-10) in a cohort of older men. 103 
 104 
METHODS 105 
Study Design 106 
The Osteoporotic Fractures in Men Study (MrOS) is a prospective observational cohort study designed to 107 
determine risk factors for osteoporosis and age-related medical conditions in men 65 years of age and older. This 108 
study is conducted at six centers in the United States: Birmingham, Alabama; Minneapolis, Minnesota; Palo Alto, 109 
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California; Pittsburgh, Pennsylvania; Portland, OR; and San Diego, California. Participants were recruited by 110 
mailings to the Department of Motor Vehicles (DMV), voter registration and participant databases, community and 111 
senior newspaper features and advertisements, and targeted presentations, from March 2000 through April 2002.  112 
Exclusion criteria were (1) inability to walk without assistance from another person, (2) bilateral hip replacements, 113 
(3) inability to provide self-reported data, (4) residence not near a study site, (5) judged by an investigator to have a 114 
medical condition that would result in early death, (6) and inability to understand and sign informed consent [18, 115 
19].  116 
Vitamin D Measurements 117 
Serum concentrations of both the inactive (25OHD) and active (1,25(OH)2D) forms of vitamin D were 118 
analyzed in a random sample of men from the baseline visit of the MrOS study.  Additional assays were carried out 119 
to measure vitamin D binding protein (DBP), the major serum protein carrier of vitamin D metabolites.  Assays 120 
were completed in December 2012 using stored serum collected at the MrOS baseline visit. At the baseline visit, 121 
fasting morning blood samples were collected; serum was separated immediately after phlebotomy, and then stored 122 
at −70°C. All samples for total 25OHD remained frozen in foil wrapped vials to reduce UV exposure until assay.  123 
Measures for 25OHD2 (derived from ergocalciferol) and 25OHD3 (derived from cholecalciferol) were 124 
performed at the Mayo Clinic using mass spectrometry as previously described [20, 21]. Deuterated stable isotope 125 
(d3-25OHD) was added to a 0.2-ml serum sample as internal standard. 25OHD2, 25OHD3, and the internal standard 126 
were extracted using acetonitrile precipitation. Extracts were further purified online and analyzed by liquid 127 
chromatography/tandem mass spectrometry using multiple reaction monitoring. 25OHD2 and 25OHD3 were 128 
reported individually. The minimum detectable limit was 4 ng/ml for 25OHD2 and 2 ng/ml for 25OHD3.  Aliquots 129 
of a single serum pool were included in alternate assay runs. Using the pooled serum, the interassay coefficient of 130 
variation (CV) for 25OHD3 was 4.4%, and the intraassay CV was 4.9%.  131 
Total 1,25(OH)2D was measured at the University of Leuven in Belgium, using LC-MS/MS without 132 
derivatization [22].  The lower limit of quantitation (LLQ) was 4.3 pg/mL for 1,25(OH)2D2 and 6 pg/mL for 133 
1,25(OH)2D3.  Inter-assay CV of pooled serum at low and high serum concentrations, respectively, were 10.1% for 134 
serum with mean concentration of 7.16 pg/mL and 5.9% for serum with mean concentration of 55.8 pg/mL [23]. 135 
 DBP concentration in serum was measured by a two-site polyclonal ELISA (Genway Biotech, San Diego, 136 
CA) at the OHSU Clinical and Translational Research Institute laboratory. Intra-assay CV was 3%.  Because no 137 
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gold standard for DBP exists, we also measured DBP by a monoclonal ELISA (mELISA; R&D Systems, 138 
Minneapolis, MN) and by polyclonal radial immunodiffusion assay (Laboratory of Clinical and Experimental 139 
Endocrinology, KU Leuven, Belgium), which had intra-assay CVs of 2-4% [24]. 140 
   Free 25OHD concentrations were calculated using published mathematical models that incorporates serum 141 
concentrations of 25OHD, 1,25(OH)2D, DBP, and albumin. Primary analyses were performed with estimated free 142 
25OHD that assumed constant binding affinity across GC genotypes; however, GC-genotype-specific affinity 143 
estimates were also calculated for comparison [25]. 144 
Inflammatory Markers 145 
Cytokine assays were measured in MrOS baseline samples utilizing a random sampling scheme. The assays 146 
were completed between December, 2009, and August, 2010, using archived serum collected at baseline on 1530 147 
MrOS men as part of a MrOS ancillary study. Cytokine measures used in this analysis include CRP, IL-6, TNFα, 148 
tumor necrosis factor alpha soluble receptors (TNFα-sRI, TNFα-sRII) and interleukin-6 soluble receptor (IL6-sR).  149 
IL-10 was also measured as an anti-inflammatory measure.  150 
All cytokine assays were performed at the Laboratory for Cytokine Biochemistry, University of Vermont. 151 
The samples were thawed at 37°C and briefly centrifuged. 300 μl of serum was placed into one cryovial for testing 152 
of TNFα, TNF-αsRI and sRII, IL-10 and CRP. Approximately 230 μl were plated into two plates for IL-6 and IL-153 
6sR. The plates were refrozen at -80°C until assaying. IL-6 was measured using a high sensitivity ELISA (R&D 154 
Systems, Minneapolis, MN). The assay range is 0.16 – 12.0 pg/mL. Inter-assay CVs range from 6.11 to 8.47%. IL-155 
6sR was measured using ELISA (R&D Systems, Minneapolis, MN). [26] The assay range is 3120 – 200,000 pg/mL. 156 
Inter-assay CVs range from 4.68 to 8.83%. TNFα was measured using the Human Serum CVD3 Multiplex Kit 157 
(Millipore Corp., Billerica, MA) which is run by flow cytometry on the Bio-Rad BioPlex 200 Luminex instrument. 158 
The assay range is 0.13-2000 pg/mL. Inter-assay CVs range from 4.93 to 9.13%. TNF-αsRI and sRII were measured 159 
with an ELISA (R&D Systems, Minneapolis, MN). The normal range for TNF- αsRI in serum is 479 – 966 pg/mL 160 
and for TNF-αsRII in serum is 1003 – 3170 pg/mL. Inter-assay CVs range from 5.42% to 8.59% for TNF-αsRI and 161 
2.87 to 3.54% for TNF-αsRII. CRP was measured using the BNII nephelometer from Dade Behring utilizing a 162 
particle enhanced immunonepholometric assay. The assay range is 0.16 – 1100 ug/mL. Expected values for CRP in 163 
normal, healthy individuals are ≤ 3 ug/mL. Inter-assay CVs ranged from 1.52 to 3.68%.   164 
Covariates 165 
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Demographic characteristics such as age, race/ethnicity, clinical site, and lifestyle factors including weekly 166 
alcohol consumption and smoking history were determined at baseline by questionnaire.  Physical activity was 167 
assessed with the Physical Activity Score for the Elderly (PASE) [27]. Height (centimeters) was measured on 168 
Harpenden stadiometers, and weight (kilograms) was measured on standard balance beam or digital scales. Body 169 
mass index (BMI) was calculated as kilograms per meter squared (kg/m2). Prevalent cardiovascular disease was 170 
defined as self-report of heart attack, congestive heart failure (CHF) or angina. Diabetes, stroke history, self-reported 171 
health, surgical removal of stomach/intestine and rheumatoid arthritis at baseline were also from self-report. 172 
Participants brought in all medications they used within the last 30 days. All prescription medications recorded by 173 
the clinics were stored in an electronic medications inventory database (San Francisco Coordinating Center, San 174 
Francisco, CA).  Each medication was matched to its ingredient(s) based on the Iowa Drug Information Service 175 
(IDIS) Drug Vocabulary (College of Pharmacy, University of Iowa, Iowa City, IA) [28].   176 
Serum creatinine was measured using a variation of the Jaffe enzymatic method. Renal function was 177 
expressed as estimated glomerular filtration rate (eGFR) in ml/min/1.73 m2 using a standardized serum-creatinine 178 
based formula [29]. Total fat mass was measured from dual-energy X-ray absorptiometry (DXA) scans using 179 
Hologic QDR 4500 scanners (Hologic, Inc., Bedford, MA).     180 
Statistical Analysis 181 
All vitamin D measurements were standardized by subtracting the mean from each value and dividing by 182 
the standard deviation to facilitate comparison across measures. Correlations among inflammatory markers and 183 
between the inflammatory markers and the vitamin D measures were assessed using Spearman’s correlation 184 
coefficients. We used linear regression modeling with robust standard errors to examine the effect of standardized 185 
vitamin D measurements on each inflammatory marker.  Although the inflammatory markers are right-skewed, 186 
least-squares regression methods perform well with 500 or more observations and provide 95% confidence interval 187 
coverage for all regression coefficients [30].  Betas (β) and 95% confidence intervals (CI) from the model are 188 
reported as mean difference in the inflammatory markers per standard deviation (SD) change in vitamin D 189 
measurements. To identify any nonlinear associations between each vitamin D measure and inflammatory marker, 190 
we examined loess plots.  We created an inflammatory index by summing the number of pro-inflammatory markers 191 
in the highest quartile (CRP, IL-6, TNFα, TNFα-sRI, TNFα-sRII and IL-6sR). We then dichotomized this index into 192 
those having ≥2 inflammatory markers in the highest quartile in comparison with those having <2 inflammatory 193 
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markers in the highest quartile [4]. Logistic regression modeling was used to obtain odds ratios (OR) and 194 
corresponding 95% CI.  195 
No nonlinear associations were detected between any vitamin D measurement and inflammatory marker.  196 
The base model included age, race, clinical site, and season.  We used stepwise modeling with a probability of 197 
removal at > 0.10, forcing the base model covariates of age, site, race, season and the vitamin D measure into the 198 
model and to include all covariates that were significantly associated with each inflammatory marker. All covariates 199 
that were significantly associated with any inflammatory marker were included in the final model for all 200 
inflammatory markers.  An age-squared term was added to each model to check for non-linear association with age.  201 
There are thirty -five associations of interest (with five vitamin D metabolites by , six inflammatory markers and one 202 
anti-inflammatory marker). , tThus, we have added a footnote to our tables with a Bonferroni adjusted p-value of 203 
≤0.001 (0.05/35 = 0.001).  204 
All analyses were conducted using SAS 9.3 (Cary, NC) and STATA release 12 (StataCorp, College Station, 205 
TX).  206 
RESULTS 207 
Description and correlations 208 
Men with inflammatory markers and vitamin D measures (Figure 1) had a mean age of 74 ±6 years and 209 
mean BMI of 27 ±4 kg/m2. Most (91%) were non-Hispanic white, and 85% reported excellent or good health status. 210 
16% were taking NSAIDs, and 27% reported a history of heart attack, CHF, or angina (Table 1).  211 
All correlations between inflammatory markers and vitamin D measures were weak. IL-6 was negatively 212 
correlated with total and free 25OHD and 1,25(OH)2D measures (r = -0.21 to -0.25, p<0.001). TNFα and its soluble 213 
receptors were significantly negatively correlated with total and free 1,25(OH)2D  measures (r = -0.14 to -0.35, 214 
p<0.001) but not with 25OHD.  The strongest correlation between CRP and vitamin D measures was with DBP (r = 215 
0.23, p<0.001) (Supplemental Table 1). 216 
Inflammatory marker associations with 25OHD and 1,25(OH)2D 217 
There was a significant association between lower IL-6 and higher 25OHD (0.23 pg/mL lower IL-6 per SD 218 
increase in 25OHD, 95% CI: 0.07 to 0.38 pg/mL), and this was independent of 1,25(OH)2D and DBP (Table 2).  219 
Mean TNFα was 0.21 pg/mL lower per SD increase in 25OHD but this association was not statistically significant 220 
(95% CI: -0.64 pg/mL to 0.21 pg/mL).  Results did not change after adjusting for 1,25(OH)2D and DBP (Table 2).    221 
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Associations of IL-6 with 25OHD and 1,25(OH)2D were similar (Figure 2), but statistically significant only 222 
for 25OHD.  Mean IL-6 levels were significantly lower per SD increase in 25OHD (-0.23 pg/mL per SD, 95% CI: -223 
0.38 to -0.07) and remained significant after adjusting for 1,25(OH)2D and DBP.  Mean IL-6 levels were lower by 224 
0.20 pg/mL (95% CI: 0.0004 to 0.39 pg/mL lower)  per SD increase in 1,25(OH)2D.  This association was 225 
attenuated to after 25OHD and DBP adjustment and was no longer significant.   226 
TNFα soluble receptors I and II were positively associated with 25OHD and inversely associated with 227 
1,25(OH)2D (Figure 3).  Average TNFα soluble receptors I and II were significantly lower by- 62.05 pg/mL ( 95% 228 
CI: 26.09 to 98.01 pg/mL) for TNFα-sRI and -88.83 pg/mL (95% CI: 30.64 to 147.02 pg/mL for TNFα-sRII) per SD 229 
increase in 1,25(OH)2D.  This association was strengthened with adjustment of 25OHD and DBP (Table 2).  TNFα 230 
soluble receptors I and II were higher by 34.66 pg/mL (95% CI: -4.17 to 73.48 pg/mL) and 38.32 pg/mL (95% CI: -231 
31.14, 107.78 pg/mL) per SD increase in 25OHD.  This association was also strengthened with 1,25(OH)2D and 232 
DBP adjustment (Table 2).   233 
Odds of having ≥2 inflammatory markers in the highest quartile decreased by 25% (95% CI: 3% to 42% 234 
decrease) per SD increase in total 1,25(OH)2D and was slightly strengthened with 25OHD and DBP adjustment 235 
(Table 2).  However, 25OHD itself was not associated with odds of having ≥2 inflammatory markers in the highest 236 
quartile. 237 
Inflammatory marker associations with free 25OHD, free 1,25(OH)2D and DBP 238 
Average CRP was significantly higher for each SD increase in DBP (1.11 ug/mL higher, 95% CI: 0.45 to 239 
1.76 ug/mL higher) (Table 3).  This association did not change after adjusting for 25OHD and 1,25(OH)2D (Table 240 
2).  Although there was a significant negative correlation between CRP and free 25OHD (r=-0.12, p<0.05), there 241 
was no significant association in regression analysis (β = 0.16 ug/mL; p=0.31) (Supplemental Table 1 and Table 3).  242 
Mean IL-6 levels were lower by 0.35 pg/mL (95% CI: 0.15 to 0.55 pg/mL lower) for each SD increase in free 243 
25OHD and by 0.22 pg/mL (95% CI: 0.04 to 0.39 pg/mL lower) per each SD increase in free 1,25(OH)2D.  TNFα 244 
soluble receptor I levels were lower by 61.51 pg/mL (95% CI: 26.28 to 96.73 pg/mL lower) and TNFα soluble 245 
receptor II levels were lower by 78.72 pg/mL (95% CI: 15.72 to 141.71 pg/mL) per SD increase in free 1,25(OH)2D.  246 
Odds of having ≥2 inflammatory markers in the highest quartile decreased by 30% (95% CI: 11% to 46% 247 
decrease) for each SD increase in free 1,25(OH)2D.  There was no significant association with free 25OHD (Table 248 
3). 249 
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CRP and TNFα soluble receptors’ associations with free measures of 25OHD and 1,25(OH)2D and DBP 250 
from other assays (monoclonal ELISA (R&D Systems, Minneapolis, MN) and radioimmunodiffusion assay (RID)) 251 
were similar to the polyclonal ELISA (Genway Biotech, San Diego, CA) assay, but slightly weaker.  The CRP-DBP 252 
associations were also somewhat weaker but still statistically significant.  IL-6 associations were significant for the 253 
free D measures from the RID assay, though slightly weaker, but not significant for the free D measures from the 254 
monoclonal ELISA assay (Supplemental Table 2).  Use of GC-genotype-specific binding affinities, rather than 255 
constant affinities, in the free D estimating equations did not make a substantial difference in associations.    256 
DISCUSSION 257 
In this study of older men, 25OHD and 1,25(OH)2D were negatively associated with IL-6 with similar 258 
magnitudes. On the other hand, associations with TNFα soluble receptors were positive for 25OHD and negative for 259 
1,25(OH)2D. DBP was positively associated with CRP, and had a weak positive association with IL-6. Perhaps for 260 
this reason, free vitamin D measures, which incorporate DBP, had slightly stronger associations with IL-6 than total 261 
vitamin D measures.  We did not observe any significant associations with TNFα, IL-10, or IL-6sR. These results 262 
indicate that 1,25(OH)2D and free D do not improve upon 25OHD in population-based IL-6 studies. However, 263 
examination of both 25OHD and 1,25(OH)2D are warranted in studies of TNFα soluble receptors.   264 
Our results support the role of serum IL-6 as a marker of the proposed anti-inflammatory effects of vitamin 265 
D.  The observed associations of 25OHD and IL-6 were consistent with previous reports in older Irish adults [31], 266 
although we observed somewhat higher median IL-6 levels across the 25OHD range.  The inverse correlation 267 
between IL-6 and both total and free forms of both vitamin D metabolites supports previous reports that this 268 
cytokine is a target for vitamin D within the immune system.  This is supported by mechanistic studies [32], for 269 
example, demonstrating that 1,25(OH)2D treatment in cell cultures inhibited p38 and lowered downstream 270 
production of IL-6 [33].   271 
CRP is also an established systemic marker of inflammation, but it was not associated with either 25OHD 272 
or 1,25(OH)2D in our study but instead was associated with levels of their serum carrier, DBP.  CRP was shown to 273 
be associated with 25OHD among older Irish adults [31] and with 1,25(OH)2D3 in ankylosing spondylitis patients 274 
[9]. (ref Lange). but But CRP levels were much higher in the vitamin D deficient group in thoseat studiesy, while in 275 
MrOS, CRP remained low across the range of 25OHD and 1,25(OH)2D (<1.5 µg/ml). Similar to our results, adults 276 
in the Framingham Offspring Study had no difference in CRP by 25OHD concentration [34].  We can speculate that 277 
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the association between CRP and DBP may reflect the potential impact of systemic inflammatory cytokines on liver 278 
production of DBP [35], although a link between inflammation, CRP and DBP has not been demonstrated in other 279 
studies [36].   280 
Soluble TNFα receptors are another important marker of inflammation in that they represent potential 281 
antagonists of TNFα function. In this study, 25OHD was positively associated and 1,25(OH)2D was negatively 282 
associated with TNFα SRI and II, suggesting dichotomous functions for the two vitamin D metabolites .  We 283 
speculate that soluble TNFα receptors may be an important novel target for 25OHD as an anti-inflammatory agent. 284 
Specifically, the upregulated TNFα sRI and II may provide a sensitive mechanism by which localized conversion of 285 
25OHD to 1,25(OH)2D can abrogate inflammatory TNFα responses.      286 
An alternative hypothesis for the negative correlations between inflammatory markers and vitamin D 287 
metabolites could be that circulating cytokines regulate serum vitamin D metabolites.  The renal vitamin D-288 
activating enzyme 1α-hydroxylase (CYP27B1) is mainly regulated by serum PTH and FGF23 but extra renal 289 
production of 1,25(OH)2D by CYP247B1 is known to be induced by inflammatory cytokines such as TNFα [37-40].  290 
Further characterization of this novel component of vitamin D and inflammation will be important in future studies 291 
of vitamin D and inflammation in the elderly, especially in those with increased inflammatory disease activity such 292 
as RA patients [41]. 293 
This is the first study to compare multiple measures of vitamin D and their associations with inflammatory 294 
markers in older adults. While other studies have examined Vitamin D metabolite levels in those with SLE and RA 295 
[14, 15], the MrOS study represents a predominantly healthy older male population, non-Hispanic white population 296 
with  a very low prevalence of RA (5%).  If 1,25(OH)2D is confirmed to be an independent predictor of 297 
inflammatory state, it may be a useful marker in supplementation studies and for clinical detection of vitamin D 298 
deficiency.  In the current study, 1,25(OH)2D was more strongly associated than 25OHD with TNFα soluble 299 
receptors and with having ≥2 inflammatory markers in the top quartile. 300 
We note limitations in our study. A substantial barrier to interpretation of vitamin D and inflammation 301 
studies is the question of whether inflammation also affects vitamin D.  Due to the cross-sectional, observational 302 
nature of this analysis, we are unable to address the directionality. It is possible that inflammation affects vitamin D, 303 
rather than the reverse. For example, a recent study of  patients undergoing elective hip or knee surgery recruited 304 
from orthopedic outpatient clinics showed orthopedic surgery patients had decreases in 25OHD3,  25(OH)D and 305 
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1,25(OH)2D as a systemic inflammatory response [42, 43]. However, RCTs [6, 44-47] and in vitro evidence also 306 
support a role for 1,25(OH)2D3 on inflammation [12, 13, 25, 48] through inhibition of IL-6 and IL-8 synthesis [11].    307 
The choice of a cComposite inflammatory score is somewhat arbitrary, and .  Tthere might be more than 308 
one are multiple methods of computing a composite inflammatory score like a z-score [49].  The method we 309 
presented in this paper of examining those with two or more inflammatory markers in the top quartile has also been 310 
published previously and represents a more specific indicator of systemic inflammation than a high level of just one 311 
inflammatory marker [4, 50-52].…(ref Hopkins). 312 
While other studies have examined Vitamin D metabolite levels in those with SLE and RA [14, 15], the 313 
MrOS study a male population, non-Hispanic white population with  a very low prevalence of RA.(5%, n=34 men)  314 
Estimations and direct measurements of circulating free 25OHD are not as yet standardized, and there is no 315 
gold standard for either DBP or free 25OHD assays. This limits our ability to conclude whether free 25OHD or free 316 
1,25(OH)2D can improve the  prediction of inflammatory markers or their downstream effects on health outcomes. 317 
However, our inclusion of multiple DBP measures and their estimates of free vitamin D provides the most thorough 318 
analyses of this question to date and suggests that further studies of free 25OHD and its role in inflammation are 319 
warranted. 320 
In conclusion, IL-6 associations with 25OHD have been consistent in several population-based and clinical 321 
studies, and we observed no added information in considering free 25OHD or 1,25(OH)2D. In contrast, we observed 322 
consistently divergent associations with TNFα soluble receptors for these metabolites. Considering the importance 323 
of TNFα action in osteoclastic maturation [7, 53, 54], future studies of vitamin D should include investigations of 324 
the effects of each metabolite.  325 
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Table 1. Baseline characteristics, MrOS  326 
Characteristic Overall (N=679) 
Mean ±SD, Median (IQR) or n(%) 
Age 74 ± 6 
Race  
   White 616 (90.72) 
   African American 22 (3.24) 
   Asian 16 (2.36) 
   Hispanic 17 (2.50) 
   Other 8 (1.18) 
Vitamin D  
   25OHD (ng/ml) 25.95 ±7.98 
   Free 25OHD (nmol/L) 0.03 ±0.01 
   1,25(OH)2D (pg/ml) 64.24 ±71.72 
   Free 1,25(OH)2D (nmol/L) 0.0015 ±0.0004 
  Vitamin D binding protein (µM) 4.36 ±0.75 
Season of blood draw  
   Winter 134 (19.73) 
   Spring 174 (45.36) 
   Summer 198 (29.16) 
   Fall 173 (25.48) 
BMI (kg/m2) 27 ±4 
Total Fat Mass (kg) § 22 ±7 
Inflammatory Markers  
   CRP (ug/mL)§ a 1.44 (2.1) 
   IL-6 (pg/mL)§ a 2.37 (1.97) 
   TNFα (pg/mL)§ a 3.96 (2.54) 
Soluble Receptors  
   TNFα-sRI (pg/mL)§ a 1940.60 (593.40) 
   TNFα-sRII (pg/mL)§ a 3521.80 (938.90) 
   IL-6sR (ng/ml)§ a 49.09 (18.25) 
Anti-Inflammatory Marker  
IL-10 (pg/mL) § a 8.85 (6.93) 
Alcohol (per week)  
   0 drinks 238 (35.05) 
   1-7 drinks 323 (47.57) 
   >7 drinks 118 (17.38) 
Self-reported quality of health*  
   Excellent/Good 576 (84.96) 
   Fair/Poor/Very Poor 102 (15.04) 
PASE score† 147 ±66 
NSAIDS use§ 107 (16.49) 
Corticosteroid use§ 53 (8.17) 
Cox-II inhibitor use 51 (7.86) 
CVDba 182 (26.80) 
Stroke 51 (7.51) 
Diabetes 83 (12.22) 
Surgical removal of stomach or intestine 56 (8.25) 
Rheumatoid Arthritis 34 (5.01) 
Renal Function  
   eGFR (ml/min/(1.73m2) § 77 ±19 
   Serum creatinine (mg/dl) § 1.02 ±0.30 
* How would you rate your overall health? 327 
†  Physical activity score for the elderly 328 
a  median, inter-quartile range (IQR)  329 
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§  5 missing total fat mass, 36 missing lipids, 80 missing CRP, 83 missing IL-6, 81 missing TNFα, 66 missing, 330 
TNFα-sRI, 72 missing TNFα-sRII, 66 missing IL-6sR, 71 missing IL-10, 36 missing eGFR, 36 missing serum 331 
creatinine, 30 missing NSAIDS use, 30 missing corticosteroid use, 30 missing Cox-II inhibitor 332 
ba  defined as self-report of previous  heart attack, congestive heart failure or angina 333 
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Table 2. Associations with each inflammatory marker (βc, 95% CI) per SD increase in total vitamin D measure, MrOS  334 
 N 25OHD 1,25(OH)2D 25OHD 1,25(OH)2D DBP 
  (SD=7.98 ng/ml) (SD=71.72 pg/ml) 25OHD, 1,25(OH)2D, and DBP in the same model 
IL-6 (pg/mL)  557 -0.23 (-0.38, -0.07)** -0.20 (-0.39, -0.0004)* -0.21 (-0.37, -0.04)* -0.14 (-0.35, 0.06) 0.15 (0.007, 0.30)* 
IL-6sR (ng/mL) 571 0.39 (-.88, 1.67) 0.20 (-1.00, 1.42) 0.26 (-1.11, 1.64) 0.04 (-1.23, 1.31) 0.54 (-0.50, 1.58) 
TNFα (pg/mL) 556 -0.23 (-0.65, 0.18) -0.19 (-0.43, 0.06) -0.21 (-0.64, 0.21) -0.12 (-0.34, 0.10) 0.11 (-0.09, 0.30) 
TNFα-sRI (pg/mL) 571 34.66 (-4.17, 73.48) -62.05 (-98.01, -26.09)*** 62.30 (21.33, 103.28)** -86.53 (-124.18, -48.87)** 16.20 (-15.36, 
47.76) 
TNFα-sRII (pg/mL) 565 38.32 (-31.14, 107.78) -88.83 (-147.02, -30.64)** 79.20 (5.53, 152.88)* -118.75 (-180.45, -57.06)** 9.75 (-45.92, 65.42) 
IL-10 (pg/mL) 566 -1.18 (-4.33, 1.97) -1.77 (-3.74, 0.19) -0.77 (-3.96, 2.41) -1.62 (-3.49, 0.25) 0.83 (-0.38, 2.04) 
CRP (µg/mL) 557 0.48 (-0.44, 1.40) 0.07 (-0.35, 0.48) 0.33 (-0.58, 1.24) -0.20 (-0.66, 0.27) 1.08 (0.50, 1.65)** 
≥2 inflammatory 
markers in highest 
quartile§ (N=571) 
571 0.98 (0.77, 1.26) 0.75 (0.58, 0.97)* 1.03 (0.79, 1.35) 0.72 (0.55, 0.95)* 1.29 (1.04, 1.59)* 
cAdjusted for age, site, race, total fat mass, serum creatinine, eGFR, smoking, alcohol, season, self-reported health, diabetes, stroke, cox-II inhibitor use, surgical 335 
removal of stomach or intestine. 336 
§Among CRP, IL-6, TNFα, TNFα-sRI, TNFα-sRII, IL-6sR. Effect measure = odds ratios (95%CI).  **p≤0.01, *p≤0.05, ***p≤0.001 (Bonferroni-corrected alpha) 337 
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Table 3. Associations with each inflammatory marker (βc, 95% CI) per SD increase in free vitamin D and binding protein (DBP) measures, MrOS 340 
 N Free 25OHD 
(SD=0.01 nmol/L) 
Free 1,25(OH)2D 
(SD=0.0004 nmol/L) 
DBP 
(SD=0.75 µM) 
IL-6 (pg/mL) 557 -0.35 (-0.55, -0.15)** -0.22 (-0.39, -0.04)* 0.11 (-0.04, 0.26) 
IL-6sR (ng/mL) 571 0.20 (-1.55, 1.96) -0.02 (-1.23, 1.18) 0.59 (-0.41, 1.59) 
TNFα (pg/mL) 556 -0.36 (-0.93, 0.20) -0.21 (-0.45, 0.03) 0.06 (-0.14, 0.25) 
TNFα-sRI (pg/mL) 571 39.67 (-13.42, 92.76) -61.51 (-96.73, -26.28)** 16.70 (-14.91, 48.32) 
TNFα-sRII (pg/mL) 565 51.01 (-44.53, 146.55) -78.72 (-141.71, -15.72)* 9.86 (-44.12, 63.83) 
IL-10 (pg/mL) 566 -2.15 (-6.18, 1.88) -1.93 (-3.81, -0.05)* 0.54 (-0.76, 1.84) 
CRP (µg/mL) 557 0.16 (-0.98, 0.67) -0.40 (-0.79, -0.02)* 1.11 (0.45, 1.76)*** 
≥2 inflammatory markers 
in highest quartile§ 
(N=571) 
571 0.85 (0.61, 1.19)  0.70 (0.54, 0.89)** 1.26 (1.03, 1.55)* 
cAdjusted for age, site, race, total fat mass, serum creatinine, eGFR, smoking, alcohol, season, self-reported health, diabetes, stroke, cox-II inhibitor use, surgical 341 
removal of stomach or intestine. 342 
§Among CRP, IL-6, TNFα, TNFα-sRI, TNFα-sRII, IL-6sR. Effect measure = odds ratios (95%CI).  **p≤0.01, *p≤0.05, ***p≤0.001 (Bonferroni-corrected alpha) 343 
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Figure 1. MrOS analytic sample size, randomly selected from the full MrOS cohort (N=5994) 345 
 346 
 347 
 348 
  349 
  
Random sample of  
980 participants  with 
5 or more stored 
serum vials for 
cytokine data. 
679 participants in 
the vitamin D and 
fracture random 
cohort who had UV-
protected serum for  
Vitamin D bioassays. 
IL-6, N=557 
IL-6sR, N=571 
TNFα, N=556 
TNFα-sRI, N=571 
TNFα-sRII, N=565 
IL-10, N=565 
CRP, N=557 
≥2 inflammatory 
markers in highest 
quartile, N=571 
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Figure 2. The IL-6 association with standardized 25OHD was nearly identical to the association with 1,25(OH)2D.  Data points are predicted valuesb.  350 
 351 
 352 
b Data points and lLines are from a fully adjusted regression model (adjusted for age, site, race, total fat mass, serum creatinine, eGFR, smoking, alcohol, season, 353 
self-reported health, diabetes, stroke, cox-II inhibitor use, surgical removal of stomach or intestine) with both vitamin D measures and DBP in the same model. 354 
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Figure 3. The TNFα soluble receptors I (top panels) and II (lower panels) associations with standardized 25OHD and 1,25(OH)2D, were in opposite directions.  357 
Data points are predicted valuesb. 358 
 359 
 360 
b Data points and lLines are from a fully adjusted regression model (adjusted for age, site, race, total fat mass, serum creatinine, eGFR, smoking, alcohol, season, 361 
self-reported health, diabetes, stroke, cox-II inhibitor use, surgical removal of stomach or intestine) with both vitamin D measures and DBP in the same model.362 
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Supplemental Tables 363 
 364 
Supplemental Table 1: Spearman correlations among Vitamin D measures and inflammatory markers 365 
 Total 25OHD Free 
25OHD 
Total 
1,25(OH)
2D 
Free 
1,25(OH)
2D 
VDBP 
(polyclon
al 
ELISA) 
VDBP 
(mono-
clonal 
ELISA) 
VDBP 
(RIA) 
IL-6 TNFα TNFα-
sRI 
TNFα-sRII IL-6sR 
Total 25OHD     0.17*** 0.19*** 0.23***      
Free 25OHD 0.87***    -0.27*** -0.59*** -0.21***      
Total 1,25(OH)2D 0.35*** 0.32***   0.09 0.09* 0.17***      
Free 1,25(OH)2D 0.28*** 0.43*** 0.91***  -0.29*** -0.62*** -0.20***      
IL-6 -0.21*** -0.21*** -0.25*** -0.24*** 0.03 -0.01 -0.06      
TNFα -0.03 -0.04 -0.14*** -0.15*** 0.01 0.08 0.04 0.24***     
TNFα-sRI -0.01 -0.01 -0.35*** -0.34*** 0.03 0.04 -0.07 0.43*** 0.38***    
TNFα-sRII -0.02 -0.02 -0.31*** -0.29*** -0.004 0.03 -0.09* 0.40*** 0.42*** 0.84***   
IL-6sR 0.01 -0.01 -0.05 -0.06 0.05 0.03 0.12*** 0.13*** 0.11*** 0.15*** 0.15***  
CRP -0.04 -0.12* -0.08 -0.16*** 0.23*** 0.10* 0.16*** 0.45*** 0.18*** 0.29*** 0.26*** 0.05 
IL-10 0.09 0.06 0.002 -0.007 0.02 0.13*** 0.05 0.09* 0.38*** 0.22*** 0.24*** 0.03 
 VDBP 
(polyclonal 
ELISA) 
VDBP 
(mono-
clonal 
ELISA) 
VDBP 
(RIA) 
IL-6 TNFα TNFα-
sRI 
TNFα-
sRII 
IL-6sR Total 
25OHD 
Free 
25OHD 
Total 
1,25(OH)2D 
Free 
1,25(OH)2
D 
Total 25OHD 0.17*** 0.19*** 0.23*** -0.21*** -0.03 -0.01 -0.02 0.01     
Free 25OHD -0.27***  -0.59*** -0.21*** -0.21*** -0.04 -0.01 -0.02 -0.01 0.87***    
Total 1,25(OH)2D 0.09  0.09* 0.17*** -0.25*** -0.14*** -0.35*** -0.31*** -0.05 0.35*** 0.32***   
Free 1,25(OH)2D -0.29***  -0.62*** -0.20*** -0.24*** -0.15*** -0.34*** -0.29*** -0.06 0.28*** 0.43*** 0.91***  
CRP 0.23*** 0.10* 0.16*** 0.45*** 0.18*** 0.29*** 0.26*** 0.05 -0.04 -0.12* -0.08 -0.16*** 
IL-6 0.03 -0.01 -0.06  0.24*** 0.43*** 0.40*** 0.13***     
TNFα 0.01 0.08 0.04 0.24***  0.38*** 0.42*** 0.11***     
TNFα-sRI 0.03 0.04 -0.07 0.43*** 0.38***  0.84*** 0.15***     
TNFα-sRII -0.004 0.03 -0.09* 0.40*** 0.42*** 0.84***  0.15***     
IL-6sR 0.05 0.03 0.12** 0.13*** 0.11*** 0.15*** 0.15***      
IL-10 0.02 0.13** 0.05 0.09* 0.38*** 0.22*** 0.24*** 0.03 0.09 0.06 0.002 -0.007 
* p<0.05, ** p<0.01, ***p<0.001.  366 
 367 
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Supplement Table 2. Associations with inflammatory markers (β, 95% CI) for each SD increase in free vitamin D and binding protein (DBP measures, MrOS) 369 
 Free 25OHD Free 1,25(OH)2D DBP 
 (Using DBP from 
monoclonal ELISA) 
(Using DBP from 
RIA) 
(Using DBP from 
monoclonal ELISA) 
(Using DBP from 
RIA) 
(Using DBP from 
monoclonal ELISA) 
(Using DBP from 
RIA) 
IL-6 (pg/mL) 
(N=557) 
-0.03 (-0.20, 0.15) -0.31 (-0.51, -
0.10)** 
-.0.09 (-0.27, 0.09) -0.18 (-0.36, 0.01) 0.05 (-0.10, 0.20) 0.01 (-0.13, 0.16) 
IL-6sR (ng/mL) 
(N=571) 
0.90 (-0.19, 1.99) -0.21 (-1.95, 1.52) 0.73 (-0.33, 1.78) -0.31 (-1.50, 0.88) 0.59 (-0.51, 1.69) 1.31 (0.31, 2.32)* 
TNFα (pg/mL) 
(N=556) 
0.01 (-0.34, 0.36) -0.42 (-0.97, 0.12) 0.0003 (-0.25, 0.25) -0.25 (-0.47, -
0.03)* 
0.005 (-0.43, 0.44) 0.15 (-0.03, 0.34) 
TNFα-sRI 
(pg/mL) (N=571) 
53.24 (17.40, 89.08) 41.79 (-11.01, 
94.60) 
-5.98 (-42.05, 30.71) -64.66 (-97.47, -
31.85)** 
35.58 (0.58, 70.58)* 16.95 (-18.36, 52.26) 
TNFα-sRII 
(pg/mL) (N=565) 
2.05 (-59.55, 63.66) 57.97 (-37.49, 
153.42) 
-52.32 (-106.80, 2.16) -79.96 (-139.29, -
20.62)** 
46.27 (-11.82, 
104.35) 
0.76 (-53.54, 55.06) 
IL-10 (pg/mL) 
(N=566) 
2.71 (-1.50, 6.92) -2.22 (-6.44, 2.00) 1.56 (-0.86, 3.98) -2.11 (-3.86, -
0.37)* 
-0.66 (-4.42, 3.11) 0.92 (-0.46, 2.31) 
CRP (ug/mL) 
(N=557) 
0.27 (-0.39, 0.93) 0.24 (-1.01, 1.49) 0.09 (-0.43, 0.61) -0.19 (-0.61, 0.23) 0.44 (-0.10, 0.98) 0.70 (0.35, 1.04)*** 
≥2 inflammatory 
markers in 
highest quartile§ 
(N=571) 1.09 (0.86, 1.39) 0.89 (0.63, 1.25) 0.85 (0.68, 1.07) 0.71 (0.55, 0.91)** 1.21 (0.97, 1.51) 1.20 (0.97, 1.49) 
Adjusted for age, site, race, total fat mass, serum creatinine, eGFR, smoking, alcohol, season, self-reported health, diabetes, stroke, cox-II inhibitor use, surgical 370 
removal of stomach or intestine. 371 
§Among CRP, IL-6, TNFα, TNFα-sRI, TNFα-sRII, IL-6sR. Effect measure = odds ratios. 372 
**p≤0.01, *p<0.05, ***p≤0.001 (Bonferroni-corrected alpha) 373 
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